Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06923228 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
A Phase 2 study, sponsored by CAGE Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT06923228: Completed Phase 2 study, sponsored by CAGE Bio.
NCT06923228 is a Phase 2 study that has completed, run by CAGE Bio. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06923228, a Phase 2 study, has completed, sponsored by CAGE Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if drug CGB-500 works to treat atopic dermatitis in subjects 12 years of age or older. It will also learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 decrease the severity of atopic dermatitis on the skin? What medical problems do participants have when taking drug CGB-500? Researchers will compare CGB-500 to a an approved product (1.5% ruxolitinib) to see if CGB-500 works to treat atopic dermatitis. Participants will: Apply CGB-500 and ruxolitinib to different locations on their body twice a day for four weeks. Visit the clinic six times for checkups and tests Keep a diary of their symptoms and when they apply the product
Primary Outcome
To evaluate percent change in localized eczema area severity by using the Localized Eczema Area Severity Index (L-EASI) score from Baseline to week 4.
Interventions
- DRUG CGB-500 Ointment with 1% tofacitinib
- DRUG Ruxolitinib 1.5% Cream QD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 2 |
What the finished NCT06923228 record still lists
NCT06923228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which CGB-500 Ointment with 1% tofacitinib is the first listed.
NCT06923228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06923228 about?
NCT06923228 is a clinical study titled "A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis". The goal of this clinical trial is to learn if drug CGB-500 works to treat atopic dermatitis in subjects 12 years of age or older. It will also learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 decrease the severity of atopic dermatitis on the skin? What medi...
What is the current status of trial NCT06923228?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2025-04-21. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT06923228?
The interventions under investigation include: CGB-500 Ointment with 1% tofacitinib (DRUG), Ruxolitinib 1.5% Cream QD (DRUG).
Who is sponsoring clinical trial NCT06923228?
This trial is sponsored by CAGE Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06923228's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI